Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$68.12 USD

68.12
5,481,354

+1.62 (2.44%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $68.12 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's How Much a $1000 Investment in Edwards Lifesciences Made 10 Years Ago Would Be Worth Today

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Shilpa Mete headshot

4 GARP Stocks to Scoop Up for Maximum Returns

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RACE, GWW, ALLE and EW are some stocks that hold promise.

Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options

Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements in the options market lately.

Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes

Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.

Here's Why You Should Invest in Edward Lifesciences (EW) Now

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.

Edwards Lifesciences (EW) Down 5.9% Since Last Earnings Report: Can It Rebound?

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mark Vickery headshot

Top Stock Reports for Home Depot, Linde & Walt Disney

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Linde plc (LIN) and The Walt Disney Company (DIS).

Edwards Lifesciences' (EW) TAVR Study Outcome Favorable

Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.

ITGR vs. EW: Which Stock Is the Better Value Option?

ITGR vs. EW: Which Stock Is the Better Value Option?

STERIS (STE) Q4 Earnings Beat Estimates, Gross Margin Falls

Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.

Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates

Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.

Alcon (ALC) Q1 Earnings Surpass Estimates, 23' EPS View Up

Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

Investors are optimistic about Walgreens Boots (WBA) on consistent partnership growth and a strong focus on strategic execution.

Charles River (CRL) Q1 Earnings Top Estimates, View Narrowed

Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.

NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall

NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.

Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan

Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.

SmileDirectClub (SDC) Q1 Earnings Miss, Gross Margin Up

SmileDirectClub (SDC) Q1 revenues are affected by persistent macroeconomic headwinds.

Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised

The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.

Henry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips

Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.

Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay

Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.

Bruker's (BRKR) New Buyout to Advance Digital Transformation

Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.

Here's Why You Should Retain Abbott (ABT) Stock For Now

Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.

Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up

Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.

Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips

The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.

Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up

Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.